Supernus Pharmaceuticals (SUPN) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Peter Vozzo - Managing DirectorJack Khattar - CEO, President & DirectorTimothy Dec - Senior VP & CFOJack Padovano - Equity Research Associate - BioPharma Conference Call Participants None - AnalystStacy Ku - AnalystDavid Amsellem - Sr. Research Analyst Operator Good afternoon, and welcome to Supernus Pharmaceuticals First Quarter twenty twenty five Financial Results Conference Call. At this time, all particip ...

Corpay (CPAY) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Good day. I'd like to welcome everyone to the Corpay First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Today's call is being recorded. I would now like to turn the call over to Jim Egglestader, Investor Relations. Please go ahead. Speaker1 Good afternoon, and thank you for joining us today ...

Corpay (CPAY) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Jim Eglseder - Investor RelationsRon Clarke - Chairman and Chief Executive OfficerAlissa Vickery - Chief Accounting Officer & Interim CFOShray Gurtata - Assistant Vice PresidentSanjay Sakhrani - Managing DirectorTrevor Williams - Managing DirectorRayna Kumar - Managing Director - Fintech Equity Research Conference Call Participants Tien-tsin Huang - Senior AnalystAndrew Jeffrey - Research AnalystAndrew Schmidt - Equity Researc ...

Financial Data and Key Metrics Changes - The company reported organic revenue growth of 10% and total revenue of $413.4 million for the first quarter [12] - Adjusted EBITDA for the first quarter rose 12% to $113.8 million compared to $101.7 million in the prior year period [12] - Adjusted diluted earnings per share increased by 16% [5] - Adjusted free cash flow was $26 million, up 6% from the prior year period [6][14] - GAAP net income for the first quarter was $24.9 million, or GAAP diluted earnings per share of $0.20 [12] Business Line Data and Key Metrics Changes - Insurance Advisory Solutions (IAS) experienced organic revenue growth of 3% [6][12] - Underwriting Capacity and Technology Solutions (UCTS) saw organic revenue growth accelerate to 32% compared to 21% in the prior year [8][12] - Main Street Insurance Solutions (MIS) delivered total organic revenue growth of 10% [10][12] Market Data and Key Metrics Changes - The company noted a negative 3.5% impact from rate and exposure changes on renewals, compared to a positive 4.5% in the prior year [8] - Client retention improved year over year to approximately 92% [7] Company Strategy and Development Direction - The company aims to vertically integrate across the value chain and bring innovative third-party risk capital solutions to market [9] - The introduction of the Builder Reciprocal Insurance Exchange (BRI) is a significant milestone for growth in the builder channel [9] - The company remains confident in maintaining double-digit organic revenue growth despite macroeconomic uncertainties [10][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience and durability of the business model amid macroeconomic uncertainty [10] - The company expects organic revenue growth in the IAS business to build through the year, with a target of mid to high single-digit growth [17] - Full-year consolidated guidance remains unchanged, with expectations for revenue in the second quarter between $370 million and $380 million [17] Other Important Information - The company was recently upgraded by S&P to a B rating, with a stable outlook from Moody's [16] - The transition to a fiduciary reporting model for cash and receivables is aimed at reducing volatility in cash flow from operations [13] Q&A Session Summary Question: Organic revenue outlook for the second quarter - Management acknowledged that the IAS business is running below expectations due to project-based headwinds but remains confident in the underlying fundamentals [20][21] Question: Cash flow conversion rate on an adjusted basis - The target for free cash flow conversion remains between $150 million and $175 million for the year, with expectations to progress towards a 65% to 70% conversion rate over time [26][27] Question: Debt leverage expectations - Management confirmed expectations to bring net leverage below four times by the third quarter [30] Question: Project-based work in the second quarter - Management noted an increase in new project starts and a strong pipeline of projects anticipated to go live [36] Question: Strong organic revenue growth in UCTS - The growth was driven by strong performance in homeowners programs and the introduction of a multifamily captive [38] Question: Headwinds in IAS - Management highlighted that Q2 would be the heaviest volume quarter for cat property renewals, expecting incremental improvement in organic growth [65] Question: Employee benefits market conditions - Management indicated that the cautious business outlook among clients has impacted the employee benefits segment, but they expect visibility to improve as the year progresses [66][68]

Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals First Quarter twenty twenty five Webcast Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, Speaker1 there Speaker0 will be a question and answer session. Thank you. I would now like to ...

Financial Data and Key Metrics Changes - The company reported total revenue of $18.8 million for Q1 2025, representing a 92.2% increase year-over-year and a 9.1% increase sequentially [5][8] - Gross profit for Q1 2025 was $7.2 million, or 38.1% of revenue, compared to $2.8 million, or 28.2% of revenue in the prior year [10] - Operating loss decreased by 56.2% to $4 million compared to $9.1 million in the prior year [10] - GAAP net loss for Q1 was $7 million, down from $11.5 million in the prior year [10] - Adjusted EBITDA loss decreased 67.4% to $2 million compared to $6.3 million in the prior year [10] Business Line Data and Key Metrics Changes - MLPE revenue represented $16 million, or 84.8% of total revenues, while OESF contributed $2 million, or 10.7% [9] - The company introduced the new 22 amp TS4A series, which serves panels up to 725 watts, enhancing its product portfolio [6] Market Data and Key Metrics Changes - EMEA revenue was $11.5 million, accounting for 61.3% of total revenues, with strong growth from Italy and The Netherlands [8][9] - The Americas region generated $4.7 million, while APAC revenue was $2.6 million, or 13.6% of total revenues [9] Company Strategy and Development Direction - The company aims to continue its growth trajectory, expecting to maintain top-line growth for the remainder of 2025 [14] - The management is focused on mitigating the impact of tariffs and expanding market share, particularly in international markets [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of demand for their solutions despite economic uncertainties [14] - The company is actively working with supply chain partners to address the challenges posed by tariffs [7] Other Important Information - Cash, cash equivalents, and marketable securities totaled $20.3 million as of March 31, 2025, with a slight sequential increase [12] - The company expects Q2 2025 revenues to range between $21 million and $23 million, with adjusted EBITDA projected to be between negative $1.5 million and positive $0.5 million [13] Q&A Session Summary Question: How do you break down the growth between improving conditions with current distributors and market share gains? - Management noted that most growth is attributed to increased market share, with existing distributors expanding their footprint [19][20] Question: What factors are contributing to market share gains? - The company highlighted a broad product offering, backward compatibility, and ease of installation as key factors driving market share [22][24] Question: Can you provide insight into the impact of tariffs on revenue? - Management indicated that approximately 5% of Q1 revenue was affected by the China tariff, with efforts underway to mitigate this impact [7][36] Question: What is the outlook for the second half of 2025? - Management expressed confidence in their guidance, supported by a growing backlog and positive market expectations [42][43] Question: How is the company managing the $50 million convertible due in January 2026? - The counterparty is being flexible, and the company is actively working on refinancing options [46][47] Question: What is the demand for off-grid products? - Management noted growing demand for off-grid solutions, particularly in the Midwest and South regions [40] Question: How is the company addressing inventory and sourcing challenges? - The company has sufficient inventory to mitigate tariff impacts in the short term and is exploring alternative sourcing options in Korea and Japan [60][61]

Financial Data and Key Metrics Changes - The company reported total revenues of $898 million for Q1 2025, with a year-over-year growth of 9% for Xywav and 10% for Epidiolex [8][29][30] - Adjusted net income was impacted by a $172 million charge related to Xyrem antitrust litigation settlements, reducing GAAP and non-GAAP EPS by $2.38 and $2.34 respectively [31][36] - The company affirmed its total revenue guidance for 2025, maintaining a range of $4.15 billion to $4.4 billion, representing a 5% year-over-year growth at the midpoint [36][38] Business Line Data and Key Metrics Changes - The neuroscience portfolio, led by Xywav, generated approximately $431 million in total revenue, with Xywav net product sales at $345 million, a 9% increase year-over-year [12][8] - Epidiolex had net product sales of approximately $218 million, reflecting a 10% increase year-over-year, driven by underlying demand and favorable U.S. payer mix [15][17] - Oncology product sales were approximately $94 million, a decrease of 8% year-over-year, primarily due to changes in pediatric treatment protocols affecting Rylase sales [18][30] Market Data and Key Metrics Changes - The company reported approximately 14,600 active Xywav patients, with a net increase of 450 patients compared to Q4 2024, indicating strong market penetration [14] - The idiopathic hypersomnia market saw a 39% increase in patient adds over the last twelve months, reflecting successful disease education campaigns [90] Company Strategy and Development Direction - The company is focused on expanding its oncology portfolio, with a supplemental new drug application submitted for Zepzelca to include first-line maintenance therapy in extensive-stage small cell lung cancer [9][21] - The acquisition of Chimerix is expected to enhance the company's presence in rare oncology and provide a near-term commercial opportunity with doravaprone [10][25] - The company aims to maintain financial flexibility and operational excellence while navigating potential tariff impacts [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the top-line revenue guidance and highlighted the potential for growth in the oncology portfolio with upcoming regulatory approvals [11][36] - The company remains optimistic about the blockbuster potential of Epidiolex and the growth trajectory of Xywav, despite near-term headwinds in oncology [9][17] Other Important Information - The company is advancing its R&D pipeline, with key trials expected to read out in the second half of 2025, including the Horizon GEA-one Phase III trial [10][22] - The company has sufficient inventory to meet its 2025 needs, mitigating potential impacts from tariffs [33][34] Q&A Session Summary Question: Supply chain and Xywav production capabilities - The company confirmed it has a U.S. supplier for Xywav with sufficient capacity to meet U.S. needs, which could mitigate tariff exposure [46][47] Question: Manufacturing footprint and potential tariff impacts - The company has multiple manufacturing locations, including a U.S. CMO and facilities in Ireland and the UK, providing flexibility in response to potential tariffs [51][52] Question: Zepzelca's growth trajectory amidst competition - Management expects Zepzelca to return to growth, driven by upcoming data presentations and potential inclusion in treatment guidelines [59][60] Question: Chimerix acquisition rationale - The acquisition aligns with the company's strategy to address unmet medical needs in oncology and is expected to provide a near-term commercial opportunity [69][70] Question: Rylase growth in the adolescent and young adult market - Management indicated that education efforts are ongoing, and they expect normalization of Rylase revenues in the second quarter of 2025 [74][75]

HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Powell Industries, Inc. (NASDAQ: POWL), a leading supplier of custom-engineered solutions for the management, control and distribution of electrical energy, today announced results for the second quarter of Fiscal 2025 ended March 31, 2025. All comparisons are to the second quarter of Fiscal 2024, unless otherwise noted. Second Quarter Key Financial Highlights: Revenues totaled $279 million, an increase of 9%;Gross profit of $83 million, or 29.9% of revenue;Net inc ...

Core Viewpoint - Air Lease Corporation (AL) reported strong first-quarter 2025 results, with earnings and revenues exceeding expectations, driven by increased rental revenues and aircraft sales, despite higher interest expenses [1][2]. Financial Performance - Quarterly earnings per share (EPS) reached $1.51, surpassing the Zacks Consensus Estimate of $1.24, marking a 15.3% year-over-year improvement [1]. - Total revenues amounted to $738.3 million, exceeding the Zacks Consensus Estimate of $710.8 million, and grew 11.3% year over year [2]. Revenue Breakdown - Revenues from the rental of flight equipment increased by 5% year over year to $645 million, attributed to fleet growth, although offset by a $12.7 million decrease in end-of-lease revenue [4]. - Revenues from aircraft sales, trading, and other sources surged by 90% year over year to $93 million, driven by heightened sales activity, including $61 million in gains from the sale of 16 aircraft [4]. Operating Expenses and Financial Position - Operating expenses rose by 13.4% year over year to $598.6 million [5]. - As of March 31, 2025, Air Lease owned 487 aircraft with a net book value of $28.6 billion, and the total fleet size was 804 [5]. - Cash and cash equivalents at the end of the first quarter were $456.62 million, down from $472.55 million in the previous quarter, while debt financing decreased to $19.8 billion from $20.2 billion [6]. Management Commentary - The CEO highlighted a strong quarter characterized by fleet expansion, significant sales gains, and insurance settlements related to aircraft in Russia, while noting no aircraft deliveries to countries with reciprocal tariffs [3]. - The company continues to benefit from robust global aircraft demand amid significant supply constraints [3].

Electronic trading platform MarketAxess Holdings Inc. (MKTX) is set to report first-quarter 2025 results on May 7, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $1.82 per share on revenues of $210.6 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)First-quarter earnings estimates have been revised downward over the past 60 days. The bottom-line projection indicates a decrease of 5.2% from the year-ag ...